| Literature DB >> 34742392 |
Kelsi Swope1, Josh Morton2, Gregory P Pogue2, Steve Hume2, Michael H Pauly3, John Shepherd2, Carrie A Simpson2, Barry Bratcher2, Kevin J Whaley4, Larry Zeitlin4, Keith R Davis5, Hugh Haydon2.
Abstract
Monoclonal antibodies (mAbs) hold great promise for treating diseases ranging from cancer to infectious disease. Manufacture of mAbs is challenging, expensive, and time-consuming using mammalian systems. We describe detailed methods used by Kentucky BioProcessing (KBP), a subsidiary of British American Tobacco, for producing high quality mAbs in a Nicotiana benthamiana host. Using this process, mAbs that meet GMP standards can be produced in as little as 10 days. Guidance for using individual plants, as well as detailed methods for large-scale production, are described. These procedures enable flexible, robust, and consistent production of research and therapeutic mAbs.Entities:
Keywords: Antibody; Drug manufacture; Infectious disease; Nicotiana benthamiana; Plant-made pharmaceuticals; Protein purification; Therapeutic
Mesh:
Substances:
Year: 2021 PMID: 34742392 DOI: 10.1016/bs.mie.2021.05.011
Source DB: PubMed Journal: Methods Enzymol ISSN: 0076-6879 Impact factor: 1.600